drugset / Trial / NCT02270632
A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX
RandomizedParallel-groupTriple-blindTreatment
Summary
A multicenter, randomized, parallel assignment, double blind, placebo-controlled, safety/efficacy phase II study of two different dosages of subcutaneous F8IL10 in patients with active rheumatoid arthritis receiving MTX.
Timeline
- Start
- 2014-10-01
- Primary completion
- 2019-04
- Completion
- 2023-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F8IL10 | Monoclonal antibody | 30 ug/kg | Subcutaneous |
| Subject | F8IL10 | Monoclonal antibody | 160 ug/kg | Subcutaneous |
| Background | MTX | Unknown | — | — |